PT  - JOURNAL ARTICLE
AU  - Anu Autio
AU  - Petri J. Vainio
AU  - Sami Suilamo
AU  - Antti Mali
AU  - Jani Vainio
AU  - Tiina Saanijoki
AU  - Tommi Noponen
AU  - Helena Ahtinen
AU  - Pauliina Luoto
AU  - Mika Teräs
AU  - Sirpa Jalkanen
AU  - Anne Roivainen
TI  - Preclinical Evaluation of a Radioiodinated Fully Human Antibody for In Vivo Imaging of Vascular Adhesion Protein-1–Positive Vasculature in Inflammation
AID  - 10.2967/jnumed.113.120295
DP  - 2013 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1315--1319
VI  - 54
IP  - 8
4099  - http://jnm.snmjournals.org/content/54/8/1315.short
4100  - http://jnm.snmjournals.org/content/54/8/1315.full
SO  - J Nucl Med2013 Aug 01; 54
AB  - Vascular adhesion protein-1 (VAP-1) is an endothelial glycoprotein mediating leukocyte trafficking from blood to sites of inflammation. BTT-1023 is a fully human monoclonal anti-VAP-1 antibody developed to treat inflammatory diseases. In this study, we preclinically evaluated radioiodinated BTT-1023 for inflammation imaging. Methods: Rabbits were intravenously injected with radioiodinated BTT-1023. Distribution and pharmacokinetics were assessed by PET/CT up to 72 h after injection. Human radiation dose estimates for 124I-BTT-1023 were extrapolated. Additionally, rabbits with chemically induced synovitis were imaged with 123I-BTT-1023 SPECT/CT. Results: Radioiodinated BTT-1023 cleared rapidly from blood circulation and distributed to liver and thyroid. Inflamed joints were delineated by SPECT/CT. The estimated human effective dose due to 124I-BTT-1023 was 0.55 mSv/MBq, if blockage of thyroid uptake is assumed. Conclusion: The radioiodinated BTT-1023 was able to detect mild inflammation in vivo. Clinical 124I-BTT-1023 PET studies with injected radioactivity of 0.5–0.7 MBq/kg may be justified.